Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine

WANG-HUEI SHENGIeong, Si-ManSi-ManIeongLin, Pin-HungPin-HungLinMING-JU HSIEHHUNG-CHIH YANGPan, Ching-FuChing-FuPanTAI-LING CHAOSUI-YUAN CHANGSHAN-CHWEN CHANG2022-10-242022-10-242023-020929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/623943The efficacy and safety of coronavirus disease 2019 (COVID-19) booster vaccines remain limited. We investigated the immunogenicity and adverse events of the third dose of mRNA vaccines in healthy adults.enCoronavirus disease 2019 (COVID-19); Immune response; Messenger RNA vaccine; Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)[SDGs]SDG3Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccinejournal article10.1016/j.jfma.2022.09.004361272062-s2.0-85138594194https://api.elsevier.com/content/abstract/scopus_id/85138594194